1.Factors influencing on the Quality of Life in Older Adults after Total Knee Replacement: The Relevance to Pain, Range of Motion, Depression, Social Support and Sense of Coherence.
Journal of Korean Academy of Community Health Nursing 2017;28(4):494-503
PURPOSE: This study is to grasp factors influencing the quality of life in older adults after total knee replacement. METHODS: This study was conducted with 165 older adults who had TKR at four orthopedic hospitals in D city. Data were analyzed using one-way ANOVA, independent t-test, Pearson's correlation, and stepwise multiple linear regression with SPSS 19.0 software. RESULTS: Pain and depression were negatively correlated with range of motion, social support, while sense of coherence was positively correlated with quality of life. Sense of coherence (43%, β=.40), pain (8%, β=−.30), and depression (3%, β=−.20) on the Physical Component Summary in the quality of life have significant explanatory power of 54%. Sense of coherence (49%, β=.44), social support (6%, β=.25), and depression (3%, β=−.22) on the Mental Component Summary in the quality of life have significant explanatory power of 58%. CONCLUSION: This study suggests developing a program to improve the quality of life in older adults who had TKR, considering factors such as sense of coherence.
Adult*
;
Arthroplasty, Replacement, Knee*
;
Depression*
;
Hand Strength
;
Humans
;
Linear Models
;
Orthopedics
;
Quality of Life*
;
Range of Motion, Articular*
;
Sense of Coherence*
2.The Relationship among Subjective Health Status, Wisdom, and Self-care Agency in Korean Older Adults.
Journal of Korean Academy of Community Health Nursing 2015;26(4):355-363
PURPOSE: This study identified the relationships among subjective health status, wisdom, and self-care agency of Korean older adults. METHODS: The participants were 274 older adults from Daegu, aged over 65 years. Data were collected by visiting two social welfare centers, two senior welfare centers, and nine senior centers in Daegu from January 18 to February 5, 2013. Data were analyzed through one-way ANOVA, independent t-test, Pearson's correlation, and stepwise multiple linear regression using the IBM SPSS/WIN 19.0 statistical program. RESULTS: A significant positive correlation was found among older adults' subjective health status, wisdom, and self-care agency. Self-care agency was affected by wisdom (47%, beta=.55), the physical component summary (18%, beta=.31) and mental component summary (1%, beta=.12) of subjective health status, and the absence of disease (2%, beta=.13). CONCLUSION: This study suggests that nursing interventions to promote self-care agency in older adults should be developed based on the characteristics of their subjective health status and wisdom.
Adult*
;
Daegu
;
Humans
;
Linear Models
;
Nursing
;
Self Care*
;
Senior Centers
;
Social Welfare
3.Factors Affecting Highly Educated Elders' Diabetic Health Leader Attitude.
Kiwol SUNG ; Jiran NAM ; Mijin YU
Journal of Korean Academy of Community Health Nursing 2014;25(2):119-127
PURPOSE: This study was done to identify the relationships among diabetic health leader attitude, diabetic knowledge, and health conservation in highly educated elders. METHODS: The participants were 119 elders aged 65 or more who were attending the senior welfare centers in D and K City and had at least a high school degree. Data were collected from June 10 to July 7 in 2013. Data analysis included one-way ANOVA, independent t-test, Pearson's correlation, and stepwise multiple regression, done with the SPSS/WIN 19.0 program. RESULTS: A positive correlation was found among diabetic health leader attitude, diabetic knowledge, and health conservation. Health conservation explained 26% (beta=.31) and diabetic knowledge explained 2% (beta=.18) of the variance in diabetic health leader attitude. CONCLUSION: The results indicate that to increase diabetic health leader attitude among highly educated elders, health leader programs are needed for increasing their diabetic knowledge and health conservation.
Aged
;
Diabetes Mellitus
;
Humans
;
Statistics as Topic
4.Tenectomy and Posterior Tenectomy of the Superior Oblique for Superior Oblique Overaction.
Mijin KIM ; Sung Jun KIM ; Young Suk YU
Journal of the Korean Ophthalmological Society 2012;53(6):813-818
PURPOSE: The authors of the present study compared the effects of tenectomy and posterior tenectomy of the superior oblique for treating superior oblique overaction (SOOA). METHODS: The records of 30 eyes of 19 patients who underwent tenectomy or posterior tenectomy of the superior oblique alone or in combination with surgery on other horizontal rectus muscles from April 2005 through November 2010 were reviewed. The review was performed in 3 patients who underwent unilateral superior oblique tenectomy, 5 patients who underwent unilateral superior oblique posterior tenectomy, 3 patients who underwent bilateral superior oblique tenectomy, 6 patients who underwent bilateral superior oblique posterior tenectomy, and 2 patients who underwent superior oblique posterior tenectomy and tenectomy. RESULTS: The mean age of the patients was 14.2 years, and the mean follow-up period was 20 months. Through superior oblique tenectomy (11 eyes) and superior oblique posterior tenectomy (19 eyes), the amount of SOOA decreased from +2.27 to +0.09 and from +1.84 to +0.93, respectively. Except for 1 out of 11 eyes with superior oblique tenectomy, SOOA was completely corrected, although SOOA remained in 6 eyes after posterior tenectomy. Therefore, the correctional effects of the 2 methods differed; both procedures showed insignificant correctional effects on vertical strabismus. CONCLUSIONS: Superior oblique tenectomy has a superior long-term weakening effect; however, posterior tenectomy showed a comparable effect in the patient with moderate to severe SOOA. Both of these methods had few complications and are considered to be effective superior oblique weakening procedures.
Eye
;
Follow-Up Studies
;
Humans
;
Muscles
5.The association between idiopathic scoliosis and growth hormone treatment in short children
Mijin PARK ; Yu Jin KIM ; Kyeong Eun OH ; Eungu KANG ; Hyo-Kyoung NAM ; Young-Jun RHIE ; Kee-Hyoung LEE
Annals of Pediatric Endocrinology & Metabolism 2022;27(3):207-213
Purpose:
Idiopathic scoliosis is the most common form of scoliosis, and the risk of onset and progression has been found to correlate with growth spurts. Therefore, treatment with recombinant human growth hormone (GH) treatment in short children may initiate and/or aggravate scoliosis. The aim of this study was to investigate the relationship between idiopathic scoliosis and GH treatment in short children.
Methods:
The medical records of 113 subjects seen at the participating institution between January 2010 and December 2020 and who were diagnosed with GH deficiency and small for gestational age, had idiopathic short stature, and were treated with GH for at least one year were reviewed. Scoliosis was defined as a Cobb angle greater than 10 degrees as assessed using a spine x-ray. Clinical data and laboratory findings before and 12 months after GH treatment were compared.
Results:
There was significant increase in height, height-standard deviation score, insulin-like growth factor 1, and insulin-like growth factor binding protein 3 (p<0.001) with GH treatment. However, there were no significant differences in the average Cobb angle (6.2°±3.3° vs. 6.1°±3.5°, p=0.842) and the prevalence of scoliosis (9.7% vs. 13.3%, p=0.481) before and after one year of GH treatment. A comparative analysis of both initial Cobb angle and change in Cobb angle during GH treatment showed no relationship with other factors.
Conclusion
Although GH treatment in short children increased height and growth velocity, it was not associated with development or aggravation of idiopathic scoliosis.
6.Evaluation of a Conjugate View Method for Determination of Kidney Uptake.
Jung Kyun BONG ; Mijin YUN ; Jong Doo LEE ; Hee Joung KIM ; Hye Kyung SON ; Yun Young KWON ; Hae Jeong PARK ; Yu Seun KIM
Korean Journal of Nuclear Medicine 2005;39(3):191-199
PURPOSE: In order to obtain better quantitation of kidney uptake, this study is to evaluate a conjugate view method (CVM) using a geometric mean attenuation correction for kidney uptake and to compare it to Gate's method. MATERIALS AND METHODS: We used a Monte Carlo code, SIMIND and a Zubal phantom, to simulate kidney uptake. SIMIND was both simulated with or without scatter for the Zubal phantom. Also, a real phantom test was carried out using a dual-head gamma camera. The activity of 0.5 mCi was infused into two small cylinder phantoms of 5 cm diameter, and then, they were inserted into a cylinder phantom of 20 cm diameter. The results by the CVM method were compared with ideal data without both of attenuation and scatter and with Gate's method. The CVM was performed with or without scatter correction. The Gate's method was performed without scatter correction and it was evaluated with regards to 0.12 cm (-1) and 0.15 cm (-1) attenuation coefficients. Data were analyzed with comparisons of mean counts in the regions of interest (ROI), profiles drawn over kidney images and linear regression. Correlation coefficients were calculated with ideal data, as well. RESULTS: In the case of the computer simulation, mean counts measured from ideal data, the CVM and the Gate's method were (right: 998 +/- 209, left: 896 +/- 249), (right: 911 +/- 207, left: 815 +/- 265), and (right: 1065 +/- 267, left: 1546 +/- 267), respectively. The ideal data showed good correlation with the CVM and the correlation coefficients of the CVM, Gate's method were (right: 0.91, left: 0.93) and (right: 0.85, left: 0.90), respectively. CONCLUSION: The conjugate view method using geometric mean attenuation correction resulted in better accuracy than the Gate's method. In conclusion, the conjugate view method independent of renal depths may provide more accurate kidney uptake.
Computer Simulation
;
Gamma Cameras
;
Kidney*
;
Linear Models
7.Effect of thyroid-stimulating hormone suppression on quality of life in thyroid lobectomy patients: interim analysis of a multicenter, randomized controlled trial in low- to intermediate-risk thyroid cancer patients (MASTER study)
Ja Kyung LEE ; Eu Jeong KU ; Su-jin KIM ; Woochul KIM ; Jae Won CHO ; Kyong Yeun JUNG ; Hyeong Won YU ; Yea Eun KANG ; Mijin KIM ; Hee Kyung KIM ; Junsun RYU ; June Young CHOI ;
Annals of Surgical Treatment and Research 2024;106(1):19-30
Purpose:
Current clinical practices favor less or no thyroid-stimulating hormone (TSH) suppression for low- to intermediate-risk thyroid cancer patients who receive thyroid lobectomy. The association of TSH suppression on healthrelated quality of life (HR-QoL) in patients after thyroid lobectomy is not well studied. This study aimed to evaluate the effect of TSH suppression on patient HR-QoL after thyroid lobectomy.
Methods:
This study included patients enrolled in an ongoing, multicenter, randomized controlled study investigating the effects of TSH suppression. Patients were randomized to either the low-TSH group (TSH target range, 0.3–1.99 μIU/ mL) or the high-TSH group (TSH target range, 2.0–7.99 μIU/mL). The HR-QoL, hyperthyroidism symptom, and depression symptom questionnaires performed preoperatively and 2 weeks and 3 months postoperatively were evaluated.
Results:
Total of 669 patients (low-TSH group, 340; high-TSH group, 329) were included. Although total HR-QoL score changes were not different between the 2 groups, the high-TSH group had a significantly higher score in the physical domain at postoperative 3 months (P = 0.046). The 2 groups did not have significant differences in hyperthyroidism and depression scores.
Conclusion
In the short-term postoperative period, the physical HR-QoL scores in thyroid lobectomy patients were better when they did not receive TSH suppression. This study suggests the importance of considering HR-QoL when setting TSH suppression targets in thyroid lobectomy patients.
8.A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung LEE ; Yea Eun KANG ; Young Joo PARK ; Bon Seok KOO ; Ki-Wook CHUNG ; Eu Jeong KU ; Ho-Ryun WON ; Won Sang YOO ; Eonju JEON ; Se Hyun PAEK ; Yong Sang LEE ; Dong Mee LIM ; Yong Joon SUH ; Ha Kyoung PARK ; Hyo-Jeong KIM ; Bo Hyun KIM ; Mijin KIM ; Sun Wook KIM ; Ka Hee YI ; Sue K. PARK ; Eun-Jae JUNG ; June Young CHOI ; Ja Seong BAE ; Joon Hwa HONG ; Kee-Hyun NAM ; Young Ki LEE ; Hyeong Won YU ; Sujeong GO ; Young Mi KANG ;
Endocrinology and Metabolism 2021;36(3):574-581
Background:
Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods:
This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion
The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.
9.A Multicenter, Randomized, Controlled Trial for Assessing the Usefulness of Suppressing Thyroid Stimulating Hormone Target Levels after Thyroid Lobectomy in Low to Intermediate Risk Thyroid Cancer Patients (MASTER): A Study Protocol
Eun Kyung LEE ; Yea Eun KANG ; Young Joo PARK ; Bon Seok KOO ; Ki-Wook CHUNG ; Eu Jeong KU ; Ho-Ryun WON ; Won Sang YOO ; Eonju JEON ; Se Hyun PAEK ; Yong Sang LEE ; Dong Mee LIM ; Yong Joon SUH ; Ha Kyoung PARK ; Hyo-Jeong KIM ; Bo Hyun KIM ; Mijin KIM ; Sun Wook KIM ; Ka Hee YI ; Sue K. PARK ; Eun-Jae JUNG ; June Young CHOI ; Ja Seong BAE ; Joon Hwa HONG ; Kee-Hyun NAM ; Young Ki LEE ; Hyeong Won YU ; Sujeong GO ; Young Mi KANG ;
Endocrinology and Metabolism 2021;36(3):574-581
Background:
Postoperative thyroid stimulating hormone (TSH) suppression therapy is recommended for patients with intermediate- and high-risk differentiated thyroid cancer to prevent the recurrence of thyroid cancer. With the recent increase in small thyroid cancer cases, the extent of resection during surgery has generally decreased. Therefore, questions have been raised about the efficacy and long-term side effects of TSH suppression therapy in patients who have undergone a lobectomy.
Methods:
This is a multicenter, prospective, randomized, controlled clinical trial in which 2,986 patients with papillary thyroid cancer are randomized into a high-TSH group (intervention) and a low-TSH group (control) after having undergone a lobectomy. The principle of treatment includes a TSH-lowering regimen aimed at TSH levels between 0.3 and 1.99 μIU/mL in the low-TSH group. The high-TSH group targets TSH levels between 2.0 and 7.99 μIU/mL. The dose of levothyroxine will be adjusted at each visit to maintain the target TSH level. The primary outcome is recurrence-free survival, as assessed by neck ultrasound every 6 to 12 months. Secondary endpoints include disease-free survival, overall survival, success rate in reaching the TSH target range, the proportion of patients with major cardiovascular diseases or bone metabolic disease, the quality of life, and medical costs. The follow-up period is 5 years.
Conclusion
The results of this trial will contribute to establishing the optimal indication for TSH suppression therapy in low-risk papillary thyroid cancer patients by evaluating the benefit and harm of lowering TSH levels in terms of recurrence, metabolic complications, costs, and quality of life.